open access

Vol 64, No 3 (2013)
Review article
Published online: 2013-07-01
Submitted: 2013-07-31
Get Citation

Adipokines in the pathogenesis of idiopathic inflammatory bowel disease

Magdalena Olszanecka-Glinianowicz, Gabriela Handzlik-Orli, Bartłomiej Orlik, Jerzy Chudek
Endokrynologia Polska 2013;64(3):226-231.

open access

Vol 64, No 3 (2013)
Review article
Published online: 2013-07-01
Submitted: 2013-07-31

Abstract

Crohn’s disease (CD) and ulcerative colitis (UC) are the two common forms of idiopathic inflammatory bowel disease (IBD). The aetiology and pathogenesis of IBD are not yet known. Genetic predisposition has been suggested as playing a role in the improper immune response to commensal microbiota. The main link of IBD pathogenesis is an intestinal immune system disability after enteric infection, resulting in an uncontrolled and chronic inflammatory state. Recently, numerous studies have been focused on the role of proinflammatory cytokines as well as hormones of adipose tissue named adipokines in the pathogenesis of IBD. Adipokines have pro- and anti-inflammatory properties and can modulate the immune response. It has been shown that obesity is associated with systemic microinflammation. On the other hand, experimental studies have revealed a link between levels of some adipokines and the severity of inflammation in IBD independent of body mass. The fat deposits called ‘wrapping’ or ‘creeping’ fat envelop the intestine, and adipokines produced by this tissue play an important role in the pathogenesis of IBD. The aim of this manuscript was to review the current literature concerning the role of adipokines in the pathogenesis of IBD. (Endokrynol Pol 2013; 64 (3): 226–231)

Abstract

Crohn’s disease (CD) and ulcerative colitis (UC) are the two common forms of idiopathic inflammatory bowel disease (IBD). The aetiology and pathogenesis of IBD are not yet known. Genetic predisposition has been suggested as playing a role in the improper immune response to commensal microbiota. The main link of IBD pathogenesis is an intestinal immune system disability after enteric infection, resulting in an uncontrolled and chronic inflammatory state. Recently, numerous studies have been focused on the role of proinflammatory cytokines as well as hormones of adipose tissue named adipokines in the pathogenesis of IBD. Adipokines have pro- and anti-inflammatory properties and can modulate the immune response. It has been shown that obesity is associated with systemic microinflammation. On the other hand, experimental studies have revealed a link between levels of some adipokines and the severity of inflammation in IBD independent of body mass. The fat deposits called ‘wrapping’ or ‘creeping’ fat envelop the intestine, and adipokines produced by this tissue play an important role in the pathogenesis of IBD. The aim of this manuscript was to review the current literature concerning the role of adipokines in the pathogenesis of IBD. (Endokrynol Pol 2013; 64 (3): 226–231)
Get Citation

Keywords

leptin; adiponectin; resistin; visfatin; TNF-alpha; IL-6 Crohn’s disease; ulcerative colitis

About this article
Title

Adipokines in the pathogenesis of idiopathic inflammatory bowel disease

Journal

Endokrynologia Polska

Issue

Vol 64, No 3 (2013)

Pages

226-231

Published online

2013-07-01

Bibliographic record

Endokrynologia Polska 2013;64(3):226-231.

Keywords

leptin
adiponectin
resistin
visfatin
TNF-alpha
IL-6 Crohn’s disease
ulcerative colitis

Authors

Magdalena Olszanecka-Glinianowicz
Gabriela Handzlik-Orli
Bartłomiej Orlik
Jerzy Chudek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl